| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.076 | 0.3 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.031 | 0.3 |